Natural History Clinical Study in Adult PKU

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

7 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-20

Study Completion Date

2023-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to characterize the natural history of phenylketonuria (PKU) due to phenylalanine hydroxylase (PAH) deficiency in adults through prospective collection of clinical, cognitive, and quality of life assessments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gene Therapy Clinical Study in Adult PKU

NCT03952156

Phenylketonurias PAH Deficiency

TERMINATED PHASE1/PHASE2

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

NCT05222178

Phenylketonurias PAH Deficiency Phenylketonuria

TERMINATED PHASE1

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

NCT06147856

Phenylketonuria

WITHDRAWN PHASE1/PHASE2

Effects of Synergy on Nutrient Intake and Acceptability in Phenylketonuria (PKU)

NCT03777826

Phenylketonurias

COMPLETED NA

Evaluation of Phe Fluctuation in PKU Pts Treated With PKU GOLIKE Versus Standard Amino Acid Protein Substitute.

NCT05487378

Phenylketonurias

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phenylalanine hydroxylase (PAH) deficiency is a rare disease caused by an inborn error of metabolism. If left untreated, PAH deficiency results in progressive, irreversible neurological impairment during infancy and early childhood.

This study is designed to collect information about important PKU-related symptoms and tests to characterize the natural history of PKU due to PAH deficiency in a selected sample of adults. No new investigational treatment will be administered to participating patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phenylketonurias PKU

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-55 years at the time of informed consent
* Diagnosis of PKU due to PAH deficiency
* One plasma Phe value with a concentration of ≥ 600 μmol/L drawn at Screening and at least 1 historical Phe value ≥ 600 μmol/L in the preceding 12 months

Exclusion Criteria

* Subjects with PKU that is not due to PAH deficiency
* Alanine aminotransferase (ALT) \> 1.5x upper limit of normal (ULN) and aspartate aminotransferase (AST) \>1.5x ULN
* Alkaline phosphatase \> 1.5x ULN
* Total bilirubin \> 1.5x ULN, direct bilirubin ≥ 1.5x ULN, unless associated with Gilbert's syndrome.
* Serum creatinine \> 1.5x ULN
* Hematology values outside of the normal range (hemoglobin \< 11.0 g/dL for males or \< 10.0 g/dL for females; white blood cells (WBC) \< 3,000/μL; absolute neutrophils \< 1,500/μL; platelets \< 100,000/μL)
* Hemoglobin A1c \> 6.5% or fasting glucose \> 126 mg/dL
* Any clinically significant abnormal laboratory result at Screening, as determined by the Investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No